Cardiovascular comorbidities in patients with psoriasis;Psoriazis hastalarinda kardiyovasküler komorbiditeler cardiovascular comorbidities in patients with psoriasis

Gulhane Medical Journal

Volumn 56, Issue 1, 2014, Pages 61-63

  Balta, Ilknur ^a   Balta, Şevket ^b   Demirkol, Sait ^b  

^a Çocuk Gastroenteroloji Hepatoloji ve Beslenme Ünitesi   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cardiovascular; Comorbidity; Psoriasis

Indexed keywords

EID: 84899666538     PISSN: 13020471     EISSN: None     Source Type: Journal    
DOI: 10.5455/gulhane.30879     Document Type: Article

References (33)

1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55(5): 82935.
2. Atakan N, Doǧan S. Psoriasis, a systemic disease? Turk J Dermatol 2012; 6(3): 119-22.
3. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157(1): 68-73.
4. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296(14): 1735-41.
5. Gisondi P, FerrazziA, Girolomoni G Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18(4): 297-304.
6. Xiao J, Chen LH, Tu YT, Deng XH, Tao J. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23(11): 1311-5.
7. Baici DD, Baici A, Karazincir S, Ucar E, lyigun U, Yalci{dotless}n F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 2009; 23(1): 1-6.
8. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010; 23(2): 114-8.
9. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 2011; 131(5): 1007-10.
10. Çelik R, DervişE, Balaban D, Can G. Coexistence of Metabolic Syndrome and Psoriasis Vulgaris. Turkderm 2010; 44(4): 204-8.
11. Sommer DM, Jenisch S, Suenan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298(7): 321-8.
12. EmreS, Metin A, Demirseren DD, KilicS, IsikogluS, ErelO. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol 2012 Sep 25. doi: 10.1111/j.1468-3083.2012.04700.x. [Epub ahead of print].
13. Mc Allister-Sistilli CG, Caggiula AR, Knopf S, Rose CA, Miller AL, Donny EC. The effects of nicotine on the immune system. Psychoneuroendocrinology 1998; 23(2): 175-87.
14. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2(5): 372-7.
15. Armstrong AW, Schupp C, Bebo V{cyrillic}. Psoriasis comorbidities: results from the national psoriasis foundation surveys 2003 to2011. Dermatology 2012; 225(2): 121-6.
16. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol 1978; 99(5): 469-75.
17. Kaye JA, Li L, Jick SS. incidence of risk factors for my ocardial infarction and other vascular diseases in patients with psoriasis. BrJ Dermatol 2008; 159(4): 895-902.
18. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K{cyrillic}, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br JDermatol 2010; 162(3): 633-6.
19. Troitzsch P, Paulista Markus MR, Dörr M, Felix SB, Jünger M, et al. Psoriasis is associated with increased intima-media thickness The Study of Health in Pomerania (SHIP). Atherosclerosis 2012; 225(2): 486-90.
20. InabaY, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012; 220: 128-33.
21. Tobin AM, Kirby B. Psoriasis: an opportunity to identify cardiovascular risk. BrJ Dermatol 2009; 161(3): 719.
22. Ahlehoff O{cyrillic}, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011; 270(2): 147-57.
23. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52(2): 262-7.
24. Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46(6): 1111-8.
25. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl.2): S1-70.
26. Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis. Br J Dermatol 2007; 157(6): 1273-4.
27. Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 2005; 90(6): 3510-6.
28. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22(3): 341-4.
29. Dixon WG, Watson KD, Lunt M, Hyrich KL. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologies Register. Arthritis Rheum 2007; 56(9): 2905-12.
30. Bosello S, Santoliquido A, Zoli A, Di Campii S{cyrillic}, Flore R, Tondi P, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with longstanding severe rheumatoid arthritis. Clin Rheumatol 2008; 27(7): 833-9.
31. Hsu LN, Armstrong AW. Psoriasis and autoimmune disorders: a review of the literature. J Am Acad Dermatol. 2012; 67(5): 1076-9.
32. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286(2): 180-7.
33. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97(18): 1837-47.